Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study evaluating risk of PML in MS patients receiving fingolimod and to investigate the effect of treatment duration and age on the risk of PML

Next Previous
Search
Trial Profile

A study evaluating risk of PML in MS patients receiving fingolimod and to investigate the effect of treatment duration and age on the risk of PML

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions

Most Recent Events

  • 06 Nov 2020 New trial record
  • 13 Sep 2020 Results presented at the 8th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top